RecruitingNCT07602699
Tirzepatide for smoking cessation in people with overweight or obesity
About this title
Read the official source — NCT07602699Medication studyAges 21–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 21 years to 65 years.
- Listed locations
- Los Angeles and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 5, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 300
- Sponsor
- University of Southern California
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT07602699
- Official title
Show the full official title
A Multi-Site Trial of Tirzepatide for Smoking Cessation
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Los Angeles · Aurora · New Haven
1 more locations
- Chicago
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Southern California, a university.
Does this study involve medication?
Yes. The study involves medication, including Tirzepatide.
Who can participate?
Listed age limits: 21 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
